Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1993 1
1996 4
1997 4
1998 2
2000 1
2001 1
2002 3
2003 1
2004 6
2005 4
2006 3
2007 5
2008 12
2009 17
2010 17
2011 19
2012 19
2013 30
2014 32
2015 25
2016 33
2017 28
2018 36
2019 37
2020 43
2021 52
2022 44
2023 49
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

502 results

Results by year

Filters applied: . Clear all
Page 1
Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050.
Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Holden BA, et al. Ophthalmology. 2016 May;123(5):1036-42. doi: 10.1016/j.ophtha.2016.01.006. Epub 2016 Feb 11. Ophthalmology. 2016. PMID: 26875007 Free article. Review.
Individual studies show variations in the prevalence of myopia and high myopia between regions and ethnic groups, and there continues to be uncertainty regarding increasing prevalence of myopia. DESIGN: Systematic review and meta-analysis. METHODS: We performed a systemati …
Individual studies show variations in the prevalence of myopia and high myopia between regions and ethnic groups, and there continues to be …
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. McMurray JJ, et al. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. N Engl J Med. 2014. PMID: 25176015 Free article. Clinical Trial.
The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. ...
The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed …
Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach.
Marks S, Naidoo J. Marks S, et al. Lung Cancer. 2022 Jan;163:59-68. doi: 10.1016/j.lungcan.2021.11.016. Epub 2021 Dec 2. Lung Cancer. 2022. PMID: 34923203 Review.
Antibody-drug conjugates (ADC) are a class of anti-cancer therapy capable of transporting cytotoxic drugs directly to tumour cells, thus harnessing the strengths of both cytotoxic chemotherapy and targeted therapy. In this review we provide a comprehensive review the design …
Antibody-drug conjugates (ADC) are a class of anti-cancer therapy capable of transporting cytotoxic drugs directly to tumour cells, thus har …
Management of Immunotherapy-Related Toxicities, Version 1.2019.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL. Thompson JA, et al. J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013. J Natl Compr Canc Netw. 2019. PMID: 30865922
Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. ...
Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was …
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J. Shankar B, et al. JAMA Oncol. 2020 Dec 1;6(12):1952-1956. doi: 10.1001/jamaoncol.2020.5012. JAMA Oncol. 2020. PMID: 33119034 Free PMC article.
OBJECTIVE: To characterize multisystem irAEs, their association with survival, and risk factors for multisystem irAE development. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study carried out in 5 academic institutions worldwide included 623 patients with …
OBJECTIVE: To characterize multisystem irAEs, their association with survival, and risk factors for multisystem irAE development. DESIGN …
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, Evans TRJ, Anthoney A, Shoushtari AN, Hamid O, Gupta A, Vardeu A, Leach E, Naidoo R, Stanhope S, Lewis S, Hurst J, O'Kelly I, Sznol M. Middleton MR, et al. Clin Cancer Res. 2020 Nov 15;26(22):5869-5878. doi: 10.1158/1078-0432.CCR-20-1247. Epub 2020 Aug 18. Clin Cancer Res. 2020. PMID: 32816891 Free PMC article. Clinical Trial.
PURPOSE: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing …
PURPOSE: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a …
Aspirin in patients undergoing noncardiac surgery.
Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, Villar JC, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Robinson A, Garg AX, Rodseth RN, Botto F, Lurati Buse G, Xavier D, Chan MT, Tiboni M, Cook D, Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Eikelboom J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O, Srinathan S, Graham M, Pasin L, Le Manach Y, Gao P, Pogue J, Whitlock R, Lamy A, Kearon C, Baigent C, Chow C, Pettit S, Chrolavicius S, Yusuf S; POISE-2 Investigators. Devereaux PJ, et al. N Engl J Med. 2014 Apr 17;370(16):1494-503. doi: 10.1056/NEJMoa1401105. Epub 2014 Mar 31. N Engl J Med. 2014. PMID: 24679062 Free article. Clinical Trial.
BACKGROUND: There is substantial variability in the perioperative administration of aspirin in patients undergoing noncardiac surgery, both among patients who are already on an aspirin regimen and among those who are not. METHODS: Using a 2-by-2 factorial trial design, we …
BACKGROUND: There is substantial variability in the perioperative administration of aspirin in patients undergoing noncardiac surgery, both …
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. McMurray JJ, et al. Eur J Heart Fail. 2013 Sep;15(9):1062-73. doi: 10.1093/eurjhf/hft052. Epub 2013 Apr 5. Eur J Heart Fail. 2013. PMID: 23563576 Free PMC article. Clinical Trial.
Probiotics to prevent infantile colic.
Ong TG, Gordon M, Banks SS, Thomas MR, Akobeng AK. Ong TG, et al. Cochrane Database Syst Rev. 2019 Mar 13;3(3):CD012473. doi: 10.1002/14651858.CD012473.pub2. Cochrane Database Syst Rev. 2019. PMID: 30865287 Free PMC article.
The carry-over effect of an aquatic-based intervention in children with cerebral palsy.
Ballington SJ, Naidoo R. Ballington SJ, et al. Afr J Disabil. 2018 Oct 29;7(0):361. doi: 10.4102/ajod.v7i0.361. eCollection 2018. Afr J Disabil. 2018. PMID: 30473998 Free PMC article.
METHOD: The study used a pretest-post-test, randomised group, cross-over design. Children aged 8-12 years (n = 10) were divided into intervention (n = 5) and control (n = 5) groups. ...
METHOD: The study used a pretest-post-test, randomised group, cross-over design. Children aged 8-12 years (n = 10) were divided into …
502 results